Followers | 7 |
Posts | 513 |
Boards Moderated | 0 |
Alias Born | 04/12/2010 |
Tuesday, November 11, 2014 12:05:50 PM
"Meanwhile, Sanofi must hope a recent deal Mr. Viehbacher struck with MannKind Corp. to market the Afrezza inhaled insulin product will be a winner. Opinion is divided. Despite a crash-and-burn experience Pfizer Inc. suffered with such a product, supporters say Afrezza has a better delivery system and many diabetics don't like injectables.
Afrezza will be priced similarly to some injectable devices, but skeptics say diabetics will still have other options and payers must be convinced to give Afrezza preferential treatment for deciding reimbursement.
If the Afrezza deal sputters, one analyst says Sanofi may have to make a drastic decision.
“Sanofi will have to go big or go home,” says David Kliff of Diabetic Investor, who believes Sanofi should either acquire another company or diabetes portfolio. A prime candidate, in his view, is AstraZeneca PLC. “The simple fact is that Lilly and Novo have experience and formulary presence on their side.”
http://m.wsj.com/articles/sticking-point-sanofis-diabetes-franchise-is-crucial-to-sorting-out-a-mess-1415299834?mobile=y
In essence, as per the article, Sanofi is hoping and betting on its diabetic medications. It produces 21% of their revenue. At the moment some things have taken a turn with their top diabetic med and they need something to work out. Sanofi does not have as many products as the larger players and thus they are particularly banking on Afrezza to work out. Its a make or break. High risk high reward. Afrezza, IMO, if it works accordingly, will be pushed like a raging hot freight train by Sanofi to help restablize and then eventually break them into big player territory. They need Afrezza to work out. They dont have too many options.
Everything above is my opinion. I am NOT responsible for any influence I have on how you invest YOUR money; I INVEST MY MONEY and I am responsible for MY MONEY and that is it.
Recent MNKD News
- MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease • GlobeNewswire Inc. • 09/18/2024 10:15:00 AM
- MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference • GlobeNewswire Inc. • 09/10/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 01:11:49 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 08:25:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/30/2024 08:35:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 01:00:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 01:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 01:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 01:00:03 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 09:23:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 08:15:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 08:15:28 PM
- MannKind to Present at Upcoming Conferences • GlobeNewswire Inc. • 08/27/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:03:59 PM
- Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board • GlobeNewswire Inc. • 08/14/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 12:05:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 12:05:34 PM
- MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update • GlobeNewswire Inc. • 08/07/2024 12:00:00 PM
- US Index Futures Rise Amid Earnings Season Optimism, Oil Prices Rebound • IH Market News • 08/07/2024 09:49:12 AM
- MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease • GlobeNewswire Inc. • 07/31/2024 10:30:00 AM
- MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024 • GlobeNewswire Inc. • 07/30/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 11:50:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 11:50:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 11:50:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 11:49:45 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM